secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0001104659-24-076341
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics CEO Alder departs; CFO Mack named interim CEO, Chairman Islam becomes Executive Chairman
--------------------------------------------------------------------------------

- CEO Matthias Alder left June 25, 2024 to pursue other opportunities; separation includes 12 months salary, COBRA, accelerated vesting.
- CFO Gene Mack appointed interim CEO effective June 25, 2024 and retains CFO role with no additional compensation.
- Chairman Khalid Islam, PhD, named Executive Chairman to advise Mack until a permanent CEO is found.
- Company's lead candidate GT-02287, an allosteric small molecule for Parkinson's, is in Phase 1 clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924076341/0001104659-24-076341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924076341/tm2418441d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-076341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer